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Compared to the overwhelming amount of literature describing how epithelial-to-
mesenchymal transition (EMT)-inducing transcription factors orchestrate cellular plasticity
in embryogenesis and epithelial cells, the functions of these factors in non-epithelial con-
texts, such as melanoma, are less clear. Melanoma is an aggressive tumor arising from
melanocytes, endowedwith unique features of cellular plasticity.The reversible phenotype-
switching between differentiated and invasive phenotypes is increasingly appreciated as
a mechanism accounting for heterogeneity in melanoma and is driven by oncogenic sig-
naling and environmental cues. This phenotypic switch is coupled with an intriguing and
somewhat counterintuitive signaling switch of EMT-inducing transcription factors. In con-
trast to carcinomas, different EMT-inducing transcription factors have antagonizing effects
in melanoma. Balancing between these different EMT transcription factors is likely the key
to successful metastatic spread of melanoma.
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INTRODUCTION
Malignant melanoma is an aggressive skin cancer arising from
the melanocyte lineage. Despite extensive research efforts on the
molecular aspects of malignant melanoma, no effective therapies
exist and nearly all patients with advanced stage melanomas die
due to its distant metastases after 6–10 months (1). Melanoma is
one of the most difficult cancers to treat successfully because it
disseminates very early after the development of the initial lesion.
Melanomas are notorious for development of drug-resistance and
many patients are refractory to single-agent therapies including
newly developed drugs such as vemurafenib (2). Surgical excision
after early detection still remains the most effective therapy, but
it has only a limited impact on disseminated melanoma. Accu-
mulating evidence indicates intratumoral heterogeneity as a key
determinant of the emergence therapy-resistant cells, which lead
to treatment failure and tumor recurrence. Single-agent drugs
usually target one subpopulation of melanoma cells while other
subpopulations survive, repopulate a tumor or spread to dis-
tant sites. Characterization of melanoma subpopulations, and in
particularly the signaling events that regulate phenotypic hetero-
geneity, might lead to the development of combination therapies
targeting multiple subpopulations of tumor cells, which could
favor long-term remissions. Moreover, classifying the tumor phe-
notypes could help identify patients who might benefit from
existing and new therapeutics.
Phenotypic heterogeneity arises among melanoma cells within
the tumor as a consequence of (epi)genetic mutations, micro-
environmental cues, and reversible changes within the cells. Over
the last few years, several research groups studied distinct subpop-
ulations in melanoma and framed their observations in different
conceptual models to explain the phenotypic and functional diver-
sity of melanoma cells. In all of these models, signaling events
involved in melanoma cellular plasticity are intertwined with
transcription factors known to induce epithelial-to-mesenchymal
transitions (EMT) in epithelial context. EMT is the process in
which epithelial cells lose their epithelial characteristics, gain mes-
enchymal features, and become motile. Different EMT-controlling
transcription factors such as SNAIL, SLUG, ZEB1, and ZEB2 have
been identified and characterized thoroughly as important drivers
of EMT (3). Reactivation of EMT-inducing transcription factors
in epithelial cells promotes oncogenic transformation and dissem-
ination EMT in carcinoma cells is accompanied by an increase
in angiogenesis, invasiveness, and drug-resistance, leading to a
more aggressive tumor type. Compared to the overwhelming
amount of literature describing how these EMT transcription fac-
tors orchestrate cellular plasticity in embryogenesis and epithelial
cells, the functions of these factors in non-epithelial contexts, such
as melanoma, are not clear. This mini review highlights the mod-
els that account for phenotypic and functional heterogeneity of
melanoma and how EMT-inducing transcription factors fit into
the molecular circuitries relevant for these different models.
CLONAL EVOLUTION VS. CANCER-STEM CELL MODEL
Genetic instability that drives clonal tumor evolution is the first
model to account for tumor heterogeneity and diversity described
in 1976. This model states that (epi)genetic changes occur over
time in all tumor cells, and that cells gaining a selective advantage
will generate clones that out-compete other clones (4). Stepwise
natural selection of the fittest and most aggressive cells would
facilitate tumor progression in a linear stochastic manner.
An alternative explanation for the intratumoral heterogene-
ity in melanoma is the cancer-stem cell model. According to this
model, a tumor is composed of cell populations in various states
of differentiation, with a large subgroup of rapidly dividing and
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differentiated tumor cells and another small subgroup with a
quiescent stem cell-like phenotype responsible for tumor spread
and growth (5). Consequently, slow-cycling cancer-stem cells may
evade chemotherapeutics that usually target replicating cancer
cells. Several research groups have proposed that transcription
factors regulating EMT also generate tumor-initiating cancer-
stem cell characteristics (6–9). Evidence supporting the concept
of EMT-inducing transcription factors conferring cancer-stem cell
features to tumor cells comes mainly from epithelial-derived can-
cers, whereas, the link between melanoma stem cells and EMT acti-
vators is less clear. Typical hallmarks of malignancy in melanoma
cancer-stem cells have been associated with EMT-inducing tran-
scription factors as discussed below, but due to controversy sur-
rounding certain melanoma cancer-stem cell markers, a clear
correlation between these transcription factors and specific mark-
ers is lacking. ZEB1 downregulation in B16-F10 melanoma cells
and in its presumed cancer-stem cell CD133+ CD44+ subpopula-
tion reduced their tumor growth in vivo, yet it has not been shown
whether lack of ZEB1 effectively depletes the CD133+ CD44+
fraction in B16-F10 tumors as such (10).
PHENOTYPE-SWITCHING AND EMT MODULATORS
Some cancer types display a clear hierarchy of tumorigenic and
non-tumorigenic cells, but this hierarchy is accompanied both
by irreversible genetic instability as well as by reversible phe-
notypic changes. A third model featuring phenotypic diversity
deals with these reversible phenotypic changes in melanoma
cells referred to as phenotype-switching, independently of hier-
archical organization. This model emphasizes reversible switch-
ing between different phenotypes of proliferative and invasive
potentials. Besides cell-intrinsic factors regulating proliferation
and migration, micro-environmental cues such as nutrients, oxy-
gen, cytokines, and growth factors affect this reversible switch.
Melanoma progression does not rely solely on irreversible clonal
or lineage-driven remodeling, but can be driven by reversible
and functional reprograming of signaling routes. This functional
reprograming is centered on microphthalmia-associated tran-
scription factor (MITF), the master regulator of melanocyte dif-
ferentiation, and pigmentation genes. MITF is a lineage-specific
oncogene that is frequently amplified or overexpressed in human
melanomas (11). The role of MITF in melanoma is controversial,
as MITF levels are subjected to a tight regulation and different
levels of MITF exert different effects in melanomagenesis (12).
Hoek and Goding (13) defined two molecular signatures corre-
sponding to two opposing phenotypes: the G1-arrested invasive
phenotype with cancer-stem cell properties and the MITF-driven
non-invasive proliferative and differentiated phenotype. In this
concept, the phenotype switch can be regulated by different sig-
naling routes and MITF acts as a “rheostat” that determines the
various plasticity states. MITF-depleted cells have a more stem
cell-like phenotype, increased plasticity, and reduced proliferation,
which collectively favor tumor progression, whereas high levels
of MITF promote proliferation and differentiation (14). Anti-
senescence signaling is likely to take place in these cells because
long-term depletion of MITF in melanoma cells triggers a senes-
cence program associated with sustained growth arrest (15). The
proposed model matches the observations of Pinner et al. of
observed Brn2 and melanin (hallmarks of invasion and differ-
entiation, respectively), which are present in a mutually exclusive
manner in melanoma cells as they invade and disseminate (16).
Over the last years, several research groups have reported reversible
mechanisms of invasion that support the phenotype-switching
model (17–21). The strict dichotomy between proliferation and
invasion can be nuanced, as it has been reported that proliferation
and invasion are not always mutually exclusive states in melanoma
(22). These findings coincide with the observation that there is no
clear correlation between proliferation rate and tumorigenic cell
frequency in human melanomas (23).
The phenotypic switch is coupled with an intriguing and some-
what counterintuitive signaling switch of EMT-inducing tran-
scription factors. We and others have shown how EMT-inducing
transcription factors are crucial for acquiring an invasive or differ-
entiated state subjected to respectively low or high levels of MITF
(24, 25). We found that the transcription factor ZEB2 is strongly
expressed in migrating melanoblasts in the embryo and that this
expression persists in differentiated melanocytes in the hair folli-
cle where it is maintained throughout adult life as an important
gatekeeper of melanocyte differentiation. Although melanin pig-
ment and differentiation markers such as MITF and tyrosinase
are lost when ZEB2 is specifically deleted in the melanocytic lin-
eage, undifferentiated non-pigmented melanocytes can remain in
the hair follicle. Loss of ZEB2 is associated with loss of MITF
and subsequent dedifferentiation. In addition, an increase in ZEB1
expression has been observed. The paradoxical expression of ZEB2
in normal melanocytes also holds true for SLUG, which is strongly
expressed in neural crest-delaminated melanoblasts, melanocytes,
and benign nevi (26). These findings may invalidate the onco-
genic potential of SLUG and ZEB2 in the melanocytic lineage
because both proteins play important roles in the differentiation
of melanocytes. Indeed, both Caramel et al. (24) and Denecker
et al. (25) have shown that expression of SLUG and ZEB2 are
positive prognostic factors for melanoma patients. Besides the
effects of ZEB2 expression on MITF and cellular plasticity, ZEB2
might also have a tumor-suppressive role due to its modulation of
PTEN in a complex RNA-regulatory network in melanoma (27).
Based on human melanoma samples, a switch from ZEB2/SLUG to
ZEB1/TWIST expression indicates malignant progression. ZEB1
and TWIST induce a molecular signature associated with a TGF-β
driven profile of migration and invasion and downregulation of
MITF (24). Moreover, this signature can be reversed by ectopic
expression of ZEB2 or SLUG. ZEB1 may drive a failsafe program
for a melanoma cell to overcome the senescent state, exemplifying
why ZEB1 expression in human melanoma is inversely correlated
with MITF status. The recent work on EMT-inducing transcrip-
tion factors in melanoma leads to the idea that melanoma cells
cycle between a differentiated and state (high levels of ZEB2 and
SLUG) and a oncogenic invasive phenotype (high levels ZEB1 and
TWIST). This reversible reprograming of EMT-TF is driven by
increased MAPK-signaling activated by oncogenic BRAFV600E and
requires FRA-1, a AP-1 family member (24). Surprisingly, the sup-
pression of SLUG in melanoma inhibits metastasis in vivo (28).
This finding supports the idea that all EMT-inducing transcrip-
tion factors promote malignant tumor progression rather than
impeding it. In view of the clonal evolution model, Gupta et al.
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proposed that the paradoxical expression of SLUG in melanocytes
and benign precursor lesions prior to transformation could limit
the number of additional alterations required for clonal selec-
tion toward metastatic clones. In other words, the pre-existing
expression of SLUG in melanocytes may predispose melanoma
to its well-known metastatic potential. Although the hypothe-
sis proposed by Gupta et al. seems to oppose the current view
on the tumor-suppressive functions of SLUG in melanoma, their
observations do not contradict the plasticity model described by
Caramel et al.: the differentiation factor SLUG can allow reversion
of the ZEB1/TWIST-driven invasive phenotype toward a differen-
tiated phenotype that enables outgrowth of disseminated cancer
cells similar to a mesenchymal-to-epithelial transition (MET) in
carcinomas. The observation that SLUG can transcriptionally acti-
vate ZEB1 whereas ZEB1 is repressed by MITF suggests that a com-
plex network of positive and negative feedback loops is regulating
this reversible reprogramming (25, 29). Although EMT-inducing
transcription factors may exert antagonizing effects during devel-
opment and progression of melanoma, this antagonizing trade-off
is likely the key to successful metastatic spread and colonization
(Figure 1).
PHENOTYPE-SWITCHING AND ENVIRONMENTAL CUES
Changes in the microenvironment are presumed to direct
phenotype-switching (13). In line with this, phenotype-switching
can be initially triggered by genetic instability that sensitizes
the cells toward microenvironmental cues. Although the role of
oncogene signaling in directing the reversible reprograming of
EMT-inducing transcription factors in melanoma is well estab-
lished (30), the microenvironmental signals that contribute to
this reprograming are largely unknown. One major candidate
signaling factor directing this reversible switching is TGF-β. The
extensive interplay between Zeb transcription factors and mem-
bers of the TGF-β family in normal and pathological context of
epithelial cells is well established (3, 31). The findings suggest that
varying levels of TGF-β could also directly regulate the expres-
sion of EMT-inducing transcription factors during melanoma
phenotype-switching. TGF-β is critical in the regulation of Gli2,
which in turns has antagonistic effect on MITF expression, eventu-
ally leading to melanoma invasion and metastasis (32, 33). More-
over, Gli2 cooperates with ZEB1 to transcriptionally repress of
E-cadherin in melanoma, and TGF-β strongly enhances this com-
plex formation (34). These data identify ZEB1 as a major player
during the cadherin switch in melanoma. Whether the repression
of MITF by ZEB1 described by Denecker et al. depends on TGF-β
and a formation of the GLI2 complex formation is unknown. In
comparison, TGF-β is a key mediator of normal melanocyte stem
cell maintenance and quiescence (35). The detection of ZEB1 pro-
tein in melanocyte stem cells further implicates a TGF-β-ZEB1
circuitry relevant to both melanocyte and melanoma stemness
(Figure 1) (25). One of the microenvironmental influences pro-
moting the switch from a proliferative to an invasive phenotype
is hypoxia. Key findings from the studies by Cheli et al. (36) and
Widmer et al. (37) show that under hypoxic conditions MITF
expression is downregulated in a HIF1α-dependent fashion while
EMT-associated markers such as ZEB1, SNAIL, fibronectin (FN1),
Sparc, and matrix metalloproteinase 2 (MMP2) are increased
(36, 37). Moreover, hypoxic conditions increase the tumorigenic
potential of melanoma cells whereas pharmacological depletion of
a MITF-negative population by forskolin treatment inhibits tumor
and metastasis development. In line with this, immunohistochem-
ical analysis of melanomas showing signs of hypoxia identified a
FN1highMITFlow subpopulation expressing presumed melanoma
cancer-stem cell markers such as ABCB5, HIF2A, JARID1B, and
NGFR as well as ZEB1 and SNAIL (38).
Reversible phenotypic plasticity of melanoma cells can also be
driven by environmental inflammatory signals, e.g., it can be ini-
tiated by UV-damaged epidermal keratinocytes releasing HMGB1
and subsequent neutrophil infiltration (39). UV-dependent acti-
vation and recruitment of neutrophils facilitates angiogenesis and
migration along a path defined by endothelial cells. Inflammation-
induced phenotypic switching toward a dedifferentiated state may
underlie the mechanism by which melanoma patients develop
resistance to adoptive cell therapy (ACT) (40). ACT uses cyto-
toxic T cells to target melanoma-specific antigens, which are lost
upon the reversible dedifferentiation driven by the inflamma-
tory cytokine TNF-α. Importantly, the authors show that the
switch is reversible, melanoma cells reacquire expression of the
differentiation markers after treatment and cessation of inflam-
mation (40). The emerging concept of phenotype-switching in
melanoma points us to new therapeutic possibilities. Neverthe-
less, chemotherapy itself may provoke cancer cell populations
to adopt a reversible drug-tolerant phenotype. Sharma et al.
(41) reported that melanoma cells transiently maintain a drug-
tolerant stage through chromatin modifications and active IGF-1R
signaling (41). In a recent “differentiation therapy,” melanoma
was made susceptible to specific drugs. After methotrexate-
mediated upregulation of MITF in melanoma cells, tyrosinase
expression was induced. Subsequently, the pro-drug TMECG
was activated by tyrosinase and consequently inhibited dihy-
drofolate reductase (DHFR) leading to apoptosis of melanoma
cells (42).
BALANCING MELANOMA HETEROGENEITY
The cancer-stem cell model, the clonal evolution model, and the
phenotype-switching model are not mutually exclusive, because
clonal evolution is likely to precede cancer stemness. In addi-
tion, genetic instability in the tumor generates the necessary
genetic variation, and consequently transcriptomic and pro-
teomic diversity, which allow microenvironment-driven or cell-
intrinsic phenotype-switching. Nevertheless, the relative contri-
butions of these different sources of tumor heterogeneity may
vary depending on tumor type. Melanoma cells are endowed
with unique features of reversible cellular plasticity, they reversible
switch between non-tumorigenic and tumorigenic state. So there-
fore the cancer-stem cell model might not effectively repre-
sent tumors possessing high interconversion rate. Therefore,
phenotype-switching is increasingly appreciated as a mechanism
accounting for melanoma heterogeneity. Indeed, the cancer-stem
cell hypothesis that implies the existence of a rare stem cell
fraction was challenged with the observation that 28% of sin-
gle melanoma cells obtained from patients-derived tumors were
tumorigenic in NOD/SCID IL2Rγnull mice (43). Besides the sug-
gested influence of technical and assay-dependent factors, the high
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FIGURE 1 | Epithelial-to-mesenchymal transition-inducing
transcription factors in physiological and pathological
development of the melanocyte lineage. EMT-inducing transcription
factors regulate stemness and differentiation in melanocytes (left),
whereas they determine the oscillation between differentiated vs.
invasive cancer cells in melanoma (right). Phenotype-switching that
accounts for melanoma heterogeneity depends on a signaling switch of
different EMT-inducing transcription factors and is regulated by
microenvironmental cues, (epi)genetic instability, and oncogenic
signaling.
frequency of tumor-initiating cells could also be partially attrib-
uted to the intrinsic plasticity of melanoma. Instead of the idea
that a small subset of cells possessing cancer-stem cell charac-
teristics, the phenotypic switching model implies that most cells
can adopt an invasive stem cell-like-identity driven by microen-
vironmental cues. When melanoma cells are triggered by the
appropriate microenvironmental signals, they can readily metas-
tasize while bypassing the acquisition and selection process of
pro-invasive mutations. A proliferative and differentiated phe-
notype can be reestablished by appropriate microenvironments,
similar to MET in carcinomas (44). As described above, regain-
ing MITF and SLUG expression is beneficial for the outgrowth
of metastatic cells and may even be required for expansion of
dormant cells at distant sites. Generation of an invasive cancer-
stem cell-like subpopulation probably occurs in all tumor types,
but the probably unique way by which it predominantly arises
in melanoma exemplifies the extremely metastatic potential and
cellular plasticity of melanoma compared to many other tumor
types.
The physiological development of melanocytes is likely the key
to the unique features of cellular heterogeneity and plasticity aris-
ing during the pathological development of melanoma. Molecular
pathways active in the normal melanocyte differentiation program
and consisting of MITF and EMT-inducing transcription factors
may explain the ability of melanoma cells to easily switch toward an
invasive phenotype. It should be noted that EMT itself does not
exist in melanoma as melanocytes are not epithelial cells. EMT
plays a key role during the formation and migration of neural
crest cells. Neural crest cells are a multipotent, migratory, transient
cell population that migrates through the vertebrate embryo to
infiltrate different organs and differentiate in various cell lineages
including melanocytes. Therefore, melanocytes can be regarded as
a product of embryonic EMT.
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